UK

Two deals were priced this week in the European corporate bond market, and next week already looks busier. With a roadshow under way and four others coming up, the window before September’s European Central Bank meeting looks full.

European corporate bond investors had only had one corporate bond deal to consider in August before LafargeHolcim brought its €750m 12 year deal on Tuesday. But that lean period looks to be over as ISS Global followed with a €600m 10 year transaction on Wednesday.

The UK Debt Management Office looks likely to bring a new index-linked Gilt in the 30 year area of the curve in November after investors and banks both called for the issue. That came as the DMO firmed up plans for its next syndication, in September.

Fintech firm Paysafe has disclosed the financial structure initial lenders have put in place before they begin marketing the all-leveraged loan funding of its acquisition by CVC and Blackstone from Old Mutual and Threadneedle.

GCP Asset Backed Income Fund, the closed-end investment fund focussed on asset-backed loans, is considering another capital increase to finance future investment opportunities, according to a regulatory filing on Tuesday.

The International Swaps and Derivatives Association (ISDA) on Monday spoke up against a potential location policy for central counterparties (CCPs) after Brexit, saying that constraining euro derivatives trades' clearing to the EU 27 would increase price volatility, execution costs and systemic risk.

The UK’s vibrant market for real estate investment trust IPOs gained another deal on Monday when Warehouse Reit, a company that does what its name suggests, announced its intention to float on London’s Alternative Investment Market (AIM).

Shares in Wilmcote Holdings, the UK specialty chemicals investment company, closed 10.4% higher on Thursday after they began trading on London’s Alternative Investment Market.

Two UK corporates completed successful equity capital markets transactions in the midst of the summer lull this week, providing investors with a small amount of supply.

Just two share sales stood this week in EMEA in an otherwise barren summer market.

Oxford Immunotec, the UK diagnostics company focused on developing tests for underserved immune-regulated conditions, has priced a $40m capital increase to finance its ongoing product development programmes.

Places for People priced its debut Australian dollar transaction on August 10. The $150m five year deal was also the first by a social housing provider in Australia.